, Volume 259, Issue 11, pp 2491-2493
Date: 04 Jul 2012

4-Aminopyridine and cerebellar gait: a retrospective case series

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Sirs,

Patients with cerebellar ataxia typically walk with a broadened base of support, decreased step length, and increased gait fluctuations [5]. Temporal and spatial gait variability in patients with degenerative cerebellar disorders depends on the actual walking speed and is increased in particular during fast and slow walking [9]. The latter is a critical parameter, since increased variability is associated with a higher risk of falls [3].

The symptomatic treatment of cerebellar gait disorders is mainly based on physiotherapeutic interventions. Coordinative training leads to short-term [6] and long-term [4] improvements in motor performance. So far, there has been no pharmacotherapeutic option for the treatment of patients with cerebellar gait disorders.

4-Aminopyridine (4-AP) was recently approved for the symptomatic treatment of gait impairment in multiple sclerosis [2]. Further, 4-AP has been shown to suppress downbeat nystagmus (DBN) in cerebellar patients [7] and to reduce t